{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:15:35Z","timestamp":1790316935241,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180833"],"award-info":[{"award-number":["U10CA180833"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180882"],"award-info":[{"award-number":["U10CA180882"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase inhibitor dasatinib has been found to effectively block bevacizumab\u2010induced glioma invasion in preclinical models, which led to the hypothesis that combining bevacizumab with dasatinib could increase bevacizumab efficacy in patients with recurrent GBM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After the completion of the phase 1 component, the phase 2 trial (ClinicalTrials.gov identifier NCT00892177) randomized patients with recurrent GBM 2:1 to receive 100\u00a0mg of oral dasatinib twice daily (arm A) or placebo (arm B) on days 1 to 14 of each 14\u2010day cycle combined with 10\u00a0mg\/kg of intravenous bevacizumab on day 1 of each 14\u2010day cycle. The primary endpoint was 6\u2010month progression\u2010free survival (PFS6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 121 evaluable patients, the PFS6 rate was numerically, but not statistically, higher in arm A versus arm B (28.9% [95% CI, 19.5%\u201040.0%] vs 18.4% [95% CI, 7.7%\u201034.4%]; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.22). Similarly, there was no significant difference in the median overall survival noted between the treatment arms (7.3\u00a0months and 7.7\u00a0months, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.93). The objective response rate was 15.7% in arm A and 26.3% in arm B (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.52), but with a significantly longer duration in patients treated on arm A (16.3\u00a0months vs 2\u00a0months). The incidence of grade \u22653 toxicity was comparable between treatment arms, with hematologic toxicities occurring more frequently in arm A versus arm B (15.7% vs 7.9%) (adverse events were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). Correlative tissue analysis demonstrated an association between pSRC\/LYN signaling in patient tumors and outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite upregulation of Src signaling in patients with GBM, the combination of bevacizumab with dasatinib did not appear to significantly improve the outcomes of patients with recurrent GBM compared with bevacizumab alone.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.32340","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T10:26:07Z","timestamp":1562754367000},"page":"3790-3800","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["A phase 1 and randomized, placebo\u2010controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance\/North Central Cancer Treatment Group N0872"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-786X","authenticated-orcid":false,"given":"Evanthia","family":"Galanis","sequence":"first","affiliation":[{"name":"Department of Oncology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Keith","family":"Anderson","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Twohy","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara W.","family":"Carrero","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse G.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Dinh","family":"Tran","sequence":"additional","affiliation":[{"name":"Oncology Division Washington University School of Medicine St. Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya A.","family":"Jeyapalan","sequence":"additional","affiliation":[{"name":"Department of Neurology Tufts Medical Center Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Regions Hospital St Paul Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Radiology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Feathers","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Mayo Clinic Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[{"name":"Department of Pathology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Buckner","sequence":"additional","affiliation":[{"name":"Department of Oncology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos Z.","family":"Anastasiadis","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Mayo Clinic Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Virginia Medical Center Charlottesville Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov189"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6968"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.18718"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.018"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2005.tb00115.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-005-9097-6"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0121"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.681063"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304121.57857.38"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop027"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056505"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0575"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1366"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2307\/2529712"},{"key":"e_1_2_8_22_1","volume-title":"Classification and Regression Trees","author":"Breinman L","year":"1984"},{"key":"e_1_2_8_23_1","unstructured":"TherneauT AtkinsonB RipleyB.rpart: recursive partitioning and regression trees.https:\/\/CRAN.R-project.org\/package=rpart. Accessed June 11 2019."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov104"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707358"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26381"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0708"},{"key":"e_1_2_8_28_1","first-page":"508","article-title":"Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial","volume":"12","author":"Hasselbalch B","year":"2010","journal-title":"Neuro Oncol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0722-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605412"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq099"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.2009"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov218.08"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84876"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.7685"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov011"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.06.001"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.32340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32340","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32340","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:18:40Z","timestamp":1760267920000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/cncr.32340"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32340","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"2019-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}